Figure 3.

Therapeutic effect of dEpoB and paclitaxel in nude mice bearing MCF-7/Adr xenografts following Q2D × 5 i.v. treatment. DX-resistant human mammary adenocarcinoma (MCF-7/Adr) tissue (50 mg) was implanted s.c. into nude mice on day 0. Six-hour i.v. infusions for control, dEpoB, and paclitaxel and i.v. injections for VBL, DX, and VP-16 were given on days 8, 10, 12, 14, and 16. ⋄, control with vehicle only; □, VBL 0.8 mg/kg; ▵, Taxol 24 mg/kg; +, DX 3 mg/kg; ○, VP-16 30 mg/kg; and ×, dEpoB 30 mg/kg. The average tumor volumes of the control group on days 14, 16, and 18 were 1,281 ± 145, 1,767 ± 161 and 2,381 ± 203 mm³ (mean ± SEM; n = 5), respectively. The vehicle for 6-hr i.v. infusion was 100 μl of Cremophor/EtOH (1:1) + 3.5 ml of saline solution. The vertical bars are the SEM for the control, dEpoB, and Taxol.